Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
q1svwS5RG06t6dan
